Drug Discovery Chemistry 2014

Drug Discovery Chemistry is the leading conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists to move between concurrent meetings and create a unique program according to personal interests. New this year is Epigenetic Inhibitor Discovery which nicely complements the most popular topics from previous years: Anti-Inflammatories, Protein-Protein Interactions, Macrocyclics and Constrained Peptides, Fragment-Based Drug Discovery, and Kinase Inhibitor Chemistry. 

Conference Programs:

• Anti-Inflammatories
• Protein-Protein Interactions
• Epigenetic Inhibitor Discovery
• Macrocyclics and Constrained Peptides
• Fragment-Based Drug Discovery
• Kinase Inhibitor Chemistry

• Plenary Keynote: James Wells, Ph.D., Professor, Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California San Francisco
• Brian Albrecht, Ph.D., Senior Director, Medicinal Chemistry, Constellation Pharmaceuticals
• Dean Richard Artis, Ph.D., Senior Vice President, Molecular Discovery, Elan
• Prabhat Arya, Ph.D., Professor, Chemistry and Chemical Biology, DRILS University of Hyderabad Campus, Gachibowli, India
• Kate Ashton, Ph.D., Senior Scientist, Medicinal Chemistry, Amgen, Inc.
• Valerio Berdini, Ph.D., Associate Director, Computational Chemistry, Astex Pharmaceutical
• Paul Bonin, Principal Scientist, Assay Development and Pharmacology, Primary Pharmacology Group, Pfizer, Inc.
• Rogier C. Buijsman, Ph.D., Head, Chemistry, Netherlands Translational Research Center B.V. (NTRC)
• Julio Camarero, Ph.D., Associate Professor, Pharmacology and Pharmaceutical Sciences/Chemistry, University of Southern California
• Stuart Conway, Ph.D., Associate Professor, Chemistry, University of Oxford
• Max Cummings, Ph.D., Principal Scientist, Discovery Sciences, Janssen
• Iwan de Esch, Ph.D., Professor, Medicinal Chemistry, VU University Amsterdam, Amsterdam
• Gerald Denis, Ph.D., Associate Professor, Cancer Center, Boston University School of Medicine
• Bruce Dorsey, Ph.D., Senior Director, Medicinal Chemistry, Teva Pharmaceuticals
• José Duca, Ph.D., Head of CADD in Cambridge, Novartis Institutes for BioMedical Research, Inc.
• Istvan Enyedy, Ph.D., Senior Scientist, Chemistry, Biogen Idec
• Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.
• Wolfgang Fecke, Ph.D., Group Leader, Primary Pharmacology, UCB Pharma
• Maria Gaczynska, Ph.D., Associate Professor, Molecular Medicine, University of Texas Health Science Center at San Antonio
• Jason E. Gestwicki, Ph.D., Associate Professor, Department of Pharmaceutical Chemistry, University of California at San Francisco
• Danielle Guarracino, Ph.D., Assistant Professor, Chemistry, The College of New Jersey
• Vincent Guerlavais, Ph.D., Distinguished Scientist, Aileron Therapeutics
• Rhian Holvey, Ph.D., Postdoc, Department of Chemistry, University of Cambridge
• Edward Holson, Ph.D., Director, Medicinal Chemistry, Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard
• ChiChi Huang, Ph.D., Scientific Director, Antibody Drug Discovery, Janssen R&D, LLC
• Jian Jin, Ph.D., Associate Professor and Director, Medicinal Chemistry, Center  for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill
• Aleksey Kazantsev, Ph.D., Associate Professor, Neurology, Harvard Medical School and Massachusetts General Hospital
• Peter Kutchukian, Ph.D., Associate Principal Scientist, Screening Ops, Merck and Co.
• Jun Liang, Ph.D., Scientist, Discovery Chemistry, Genentech, Inc.
• Dustin McMinn, Ph.D., Associate Director, Medicinal Chemistry, Onyx Pharmaceuticals
• Christel Menet, Ph.D., Senior Lead, Project Director, Auto-immune disease, Galapgos
• Susanne Muller-Knapp, Ph.D., Epigenetic Project Manager, Structural Genomics Consortium (SGC), Oxford
• Elmar Nurmemmedov, Ph.D., Scientist, Molecular Experimental Medicine, The Scripps Research Institute
• Mark Peterson, Ph.D., Vice President, IP & Operations, R&D, Tranzyme Pharma Inc.
• Kamal Puri, Ph.D., Associate Director, Research, Gilead Sciences Inc.
• Jun Qi, Ph.D., Senior Research Scientist, Medical Oncology, Dana-Farber Cancer Institute
• Rick Roberts, Ph.D., Senior Scientist, Medicinal Chemistry, Almirall
• Gloria Serra, Ph.D., Professor, Medicinal Chemistry, Organic Chemistry, Facultad de Química, Universidad de la República
• Arun Shukla, Ph.D., Assistant Professor, Medicine, Duke University Medical Center
• Laura Silvian, Ph.D., Principal Scientist, Physical Biochemistry, Biogen Idec
• Daqing Sun, Ph.D., Principal Scientist, Medicinal Chemistry, Amgen
• Francisco X. Talamas, Ph.D., formerly Associate Director and Head, Virology Chemistry, Hoffmann-La Roche Inc.
• Steven J. Taylor, Ph.D., Director, Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Inc.
• Marc Thommen, Ph.D. Head Technology Platforms, Polyphor
• Erik Verner, Ph.D., Director, Chemistry, Principia Biopharma
• Xiang Wang, Ph.D., Assistant Professor, Chemistry and Biochemistry, University of Colorado at Boulder
• Zhulung Wang, Ph.D., Scientific Director, Molecular Structure, Amgen (invited)
• Anthony D. William, Ph.D., Senior Scientist, The Agency for Science, Technology and Research (A*STAR)-ICES
• Damian W. Young, Ph.D., Assistant Professor, Departments of Pathology and Immunology and Pharmacology, Assistant Director for the Center of Drug Discovery, Baylor College of Medicine
• Qinghai Zhang, Ph.D., Associate Professor, Integral Structural and Computational Biology, The Scripps Research Institute